



NDA 22184/S-008

SUPPLEMENT APPROVAL

Allergan, Inc.
Attention: Bryon Marcus C. Lim, PharmD, MS, RPh
Senior Analyst, Regulatory Affairs
2525 Dupont Drive, P.O. Box 19534
Irvine, CA 92623-9534

Dear Dr. Lim:

Please refer to your supplemental new drug application (sNDA) dated and received June 14, 2018, and your amendments, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for LUMIGAN (bimatoprost ophthalmic solution) 0.01%. This Prior Approval supplemental new drug application proposes updates to the Postmarketing Experience subsection of the prescribing information based on postmarketing surveillance reports.

APPROVAL & LABELING

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at FDA.gov.¹ Content of labeling must be identical to the enclosed labeling (text for the Prescribing Information), with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As*.²

The SPL will be accessible from publicly available labeling repositories.

¹ <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>

² We update guidances periodically. For the most recent version of a guidance, check the FDA Guidance Documents Database <https://www.fda.gov/RegulatoryInformation/Guidances/default.htm>.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in Microsoft Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes. To facilitate review of your submission(s), provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Derek Alberding, Regulatory Health Project Manager, at (240) 402-0963.

Sincerely,

{See appended electronic signature page}

Wiley A. Chambers, M.D.
(Acting) Director
Division of Ophthalmology
Office of Specialty Medicine
Center for Drug Evaluation and Research

ENCLOSURE:

- Content of Labeling
 - o Prescribing Information

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

WILEY A CHAMBERS
09/29/2020 01:34:27 PM